<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35416870</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1678-9849</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>55</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Revista da Sociedade Brasileira de Medicina Tropical</Title>
          <ISOAbbreviation>Rev Soc Bras Med Trop</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Frequency of exposure to arboviruses and characterization of Guillain Barré syndrome in a clinical cohort of patients treated at a tertiary referral center in Brasília, Federal District.</ArticleTitle>
        <Pagination>
          <StartPage>e03062021</StartPage>
          <MedlinePgn>e03062021</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0306-2021</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1590/0037-8682-0306-2021</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0037-86822022000100308</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Guillian Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy often associated with previous exposure to infectious agents.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A clinical cohort of 41 patients with GBS admitted to the Base Hospital Institute of the Federal District between May 2017 and April 2019 was followed up for 1 year. Serological tests for arbovirus detection and amplification of nucleic acids using polymerase chain reaction for zika virus (ZIKV), dengue virus (DENV), and chikungunya virus (CHIKV) were performed.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The cohort consisted of 61% men with a median age of 40 years, and 83% had GBS-triggering events. A total of 54% had Grade 4 disability, 17% had Grade 3, 12% had Grade 2, 10% had Grade 5, and 7% had Grade 1. The classic form occurred in 83% of patients. Nerve conduction evaluations revealed acute demyelinating inflammatory polyneuropathy (51%), acute motor axonal neuropathy (17%), acute sensory-motor neuropathy (15%), and indeterminate forms (17%). Four patients were seropositive for DENV. There was no laboratory detection of ZIKV or CHIKV infection. Ninety percent of patients received human immunoglobulin. Intensive care unit admission occurred in 17.1% of the patients, and mechanical ventilation was used in 14.6%. One patient died of Bickerstaff's encephalitis. Most patients showed an improvement in disability at 10 weeks of follow-up.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GBS in the Federal District showed a variable clinical spectrum, and it was possible to detect recent exposure to DENV.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Matos</LastName>
            <ForeName>Luíza Morais de</ForeName>
            <Initials>LM</Initials>
            <Identifier Source="ORCID">0000-0002-4240-4041</Identifier>
            <AffiliationInfo>
              <Affiliation>Universidade de Brasília, Faculdade de Medicina, Núcleo de Medicina Tropical, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto Hospital de Base do Distrito Federal, Unidade de Infectologia, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Borges</LastName>
            <ForeName>Ariely Teotonio</ForeName>
            <Initials>AT</Initials>
            <Identifier Source="ORCID">0000-0003-4185-251X</Identifier>
            <AffiliationInfo>
              <Affiliation>Instituto Hospital de Base do Distrito Federal, Unidade de Neurologia, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Palmeira</LastName>
            <ForeName>Aline Barbosa</ForeName>
            <Initials>AB</Initials>
            <Identifier Source="ORCID">0000-0001-7393-1488</Identifier>
            <AffiliationInfo>
              <Affiliation>Instituto Hospital de Base do Distrito Federal, Unidade de Neurologia, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lima</LastName>
            <ForeName>Vinicius Moreira</ForeName>
            <Initials>VM</Initials>
            <Identifier Source="ORCID">0000-0002-5575-872X</Identifier>
            <AffiliationInfo>
              <Affiliation>Instituto Hospital de Base do Distrito Federal, Unidade de Neurologia, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maciel</LastName>
            <ForeName>Ernane Pires</ForeName>
            <Initials>EP</Initials>
            <Identifier Source="ORCID">0000-0001-6584-9572</Identifier>
            <AffiliationInfo>
              <Affiliation>Instituto Hospital de Base do Distrito Federal, Unidade de Neurologia, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernandez</LastName>
            <ForeName>Rubens Nelson Morato</ForeName>
            <Initials>RNM</Initials>
            <Identifier Source="ORCID">0000-0003-2978-0269</Identifier>
            <AffiliationInfo>
              <Affiliation>Instituto Hospital de Base do Distrito Federal, Unidade de Neurologia, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mendes</LastName>
            <ForeName>João Pedro Lima</ForeName>
            <Initials>JPL</Initials>
            <Identifier Source="ORCID">0000-0001-7662-7692</Identifier>
            <AffiliationInfo>
              <Affiliation>Universidade de Brasília, Faculdade de Medicina, Núcleo de Medicina Tropical, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Romero</LastName>
            <ForeName>Gustavo Adolfo Sierra</ForeName>
            <Initials>GAS</Initials>
            <Identifier Source="ORCID">0000-0003-1425-926X</Identifier>
            <AffiliationInfo>
              <Affiliation>Universidade de Brasília, Faculdade de Medicina, Núcleo de Medicina Tropical, Brasília, DF, Brasil.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Rev Soc Bras Med Trop</MedlineTA>
        <NlmUniqueID>7507456</NlmUniqueID>
        <ISSNLinking>0037-8682</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001103" MajorTopicYN="Y">Arboviruses</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062606" MajorTopicYN="N">Tertiary Care Centers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071244" MajorTopicYN="Y">Zika Virus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071243" MajorTopicYN="Y">Zika Virus Infection</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>
<b>Conflict of Interest:</b> The authors declare that there is no
conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35416870</ArticleId>
        <ArticleId IdType="pmc">PMC9009888</ArticleId>
        <ArticleId IdType="doi">10.1590/0037-8682-0306-2021</ArticleId>
        <ArticleId IdType="pii">S0037-86822022000100308</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain Barré syndrome: pathogenesis, diagnosis, treatment and
prognosis. Nat Rev Neurol. 2014;10(8):469–482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25023340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wachira VK, Peixoto HM, de Oliveira MRF. Systematic review of factors associated with the development of
Guillain-Barré syndrome 2007-2017: what has changed? Trop Med Int Health. 2019;24(2):132–142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malek E, Salameh J. Guillain-Barre Syndrome. Semin Neurol. 2019;39(5):589–595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31639842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27857121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peixoto HM, Romero GAS, de Araújo WN, de Oliveira MRF. Guillain-Barré syndrome associated with Zika virus infection in
Brazil: a cost-of-illness study. Trans R Soc Trop Med Hyg. 2019;113(5):252–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wachira VK, Nascimento GL, Peixoto HM, de Oliveira MRF. Burden of Disease of Guillain-Barré Syndrome in Brazil before and
during the Zika virus epidemic 2014-2016. Trop Med Int Health. 2021;26(1):66–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33151584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO  . Identification and management of Guillain-Barré syndrome in the context
of Zika virus Interim guidance. 2016. </Citation>
        </Reference>
        <Reference>
          <Citation>Yuki N, Hartung HP. Guillian_Barré syndrome. New England Journal of Medicine. 2012;366:2294–2304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22694000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakerley BR, Uncini A, Yuki N. GBS Classification Group  Guillain-Barré and Miller Fisher syndromes - new diagnostic
classification. Nat Rev Neurol. 2014;10(9):537–544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25072194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grapperon AM, Berro M, Salort-Campana E, Verschueren A, Delmont E, Attarian S.  Revue Neurologique. 1-2. Vol. 175. Paris: 2019. GuillainBarré syndrome subtypes: A clinical electrophysiological
study of 100 patients; pp. 73–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al.  Dengue virus sero-cross-reactivity drives antibody-dependent
enhancement of infection with zika virus. Nature Immunology. 2016;(9):1102–1108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4994874</ArticleId>
            <ArticleId IdType="pubmed">27339099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinto VL, Junior, Luz K, Parreira R, Ferrinho P. Zika virus: A Review to clinicians. Acta Médica Portuguesa. 2015;28(6):760–765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26849762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinheiro TJ, Guimarães LF, Silva MTT, Soares CN. Neurological manifestations of Chikungunya and Zika
infections. Arquivos de Neuropsiquiatria. 2016;74(11):937–943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27901259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanjare HA, Mannam P, Mishra AK, Karuppusami R, Carey RAB, Abraham AM, et al.  Brain imaging in cases with positive serology for dengue with
neurologic symptoms: A clinico-radiologic correlation. American Journal of Neuroradiology. 2018;39(4):699–703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7410756</ArticleId>
            <ArticleId IdType="pubmed">29439121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterman SH, Margolis HS, Sejvar JJ. Surveillance for dengue and dengue-associated neurologic
syndromes in the United States. American Journal of Tropical Medicine &amp; Hygiene. 2015;92(5):996–998.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4426592</ArticleId>
            <ArticleId IdType="pubmed">25371183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré
syndrome. Cochrane Database Syst Rev. 2014;2014(9):CD002063–CD002063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6781841</ArticleId>
            <ArticleId IdType="pubmed">25238327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva IRF, Frontera JA, Bispo de Filippis AM, Nascimento OJMD. RIO-GBS-ZIKV Research Group  Neurologic Complications Associated with the Zika Virus in
Brazilian Adults. JAMA Neurology. 2017 Oct 01;74(10):1190–1198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710239</ArticleId>
            <ArticleId IdType="pubmed">28806453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Styczynski AR, Malta JMAS, Krow-Lucal ER, Percio J, Nóbrega ME, Vargas A, et al.  Increased rates of Guillain-Barré syndrome associated with Zika
virus outbreak in the Salvador metropolitan area, Brazil. PLoS Negl Trop Dis. 2017 Aug 30;11(8)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5595339</ArticleId>
            <ArticleId IdType="pubmed">28854206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, et al.  International Guillain-Barré Syndrome Outcome Study: protocol of
a prospective observational cohort study on clinical and biological
predictors of disease course and outcome in Guillain-Barré
syndrome. J Peripher Nerv Syst. 2017;22(2):68–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28406555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>IGOS-ZIKA©: Um estudo prospectivo para determinar a associação entre
infecções por Zika vírus e a Síndrome de Guillain-Barre (SGB) em pacientes
de áreas endêmicas para Zika, baseados no protocolo do Estudo Internacional
de Prognóstico da SGB (IGOS) Feb 29, 2016. </Citation>
        </Reference>
        <Reference>
          <Citation>Kuno G, Gómez I, Gubler DJ. Detecting artificial anti-dengue IgM immune complexes using an
enzyme-linked immunosorbent assay. Am J Trop Med Hyg. 1987;36(1):153–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3812880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson BW, Russell BJ, Lanciotti RS. Serotype-specific detection of dengue viruses in a fourplex
real-time reverse transcriptase PCR assay. J Clin Microbiol. 2005;43(10):4977–4983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1248506</ArticleId>
            <ArticleId IdType="pubmed">16207951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré
syndrome. Ann Neurol. 1990;27(Suppl):S21–S24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2194422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WMA Declaration of Hensinki  . Ethical Principles for Medical Research Involving Human
Subjects. Jul 09, 2018. </Citation>
        </Reference>
        <Reference>
          <Citation>Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al.  IGOS Consortium  Regional variation of Guillain-Barré syndrome. Brain. 2018 Oct 01;141(10):2866–2877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b
antibody syndrome. J Neurol Neurosurg Psychiatry. 2013;84(5):576–583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22984203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cea G, Jara P, Quevedo F. Características epidemiológicas del síndrome de Guillain-Barré em
población chilena: estudio hospitalario en un período de 7
años. Revista Medica de Chile. 2015;143:183–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25860360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkantrakorn K, Sukphulloprat P. Outcome of Guillain-Barré Syndrome in Tertiary Care Centers in
Thailand. Journal of Clinical Neuromuscular Disease. 2017;19(2)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29189549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Govoni V, Granieri E. Epidemiology of the Guillain- Barre syndrome. Current Opinion in Neurology. 2001;14(5):605–613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11562572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van der Meché FG, van Doorn PA. Guillain-Barre syndrome and chronic inflammatory demyelinating
polyneuropathy: immune mechanisms and update on current
therapies. Annals of Neurology. 1995;37(Suppl 1):S14–S31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8968214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravasio A, Pasquinelli M, Curro Dossi B, Neri W, Guidi C, Gessaroli M, et al.  Emilia-Romagna Study Group on Clinical and Epidemiological Problems
in Neurology  A prospective study on the incidence and prognosis of
Guillain-Barré syndrome in Emilia-Romagna region, Italy
(1992-1993) Neurology. 1997;48(1):214–221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9008520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Hakem H, Sindrup SH, Andersen H, de la Cour CD, Lassen LL, van den Berg B, et al.  Guillain-Barré syndrome in Denmark: a population-based study on
epidemiology, diagnosis and clinical severity. Journal of Neurology. 2019;266(2):440–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donofrio PD.  Continuum. 5. Vol. 23. Minneap Minn: 2017. Guillain-Barre´ Syndrome; pp. 1295–1309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28968363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakerley BR, Kokubun N, Funakoshi K, et al.  Clinical classification of 103 Japanese patients with
Guillain-Barré syndrome. J Neurol Sciences. 2016:43–47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27653863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martic V, Bozovic I, Berisavac I, Basta I, Peric S, Babic M, et al.  Three-Year Follow-Up Study in Patients with Guillain-Barré
Syndrome. Canadian Journal of Neurology Sciences. 2018;45:269–274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29756592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Méndez N, Oviedo-Pastrana M, Mattar S, Caicedo-Castro I, Arrieta G. Zika virus disease, microcephaly and Guillain-Barré syndrome in
Colombia: epidemiological situation during 21 months of the Zika virus
outbreak, 2015-2017. Arch Public Health. 2017 Nov 02;75:65–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5667031</ArticleId>
            <ArticleId IdType="pubmed">29118981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salles TS, da Encarnação Sá-Guimarães T, de Alvarenga ESL, Guimarães-Ribeiro V, de Meneses MDF, de Castro-Salles PF, et al.  History, epidemiology and diagnostics of dengue in the American
and Brazilian contexts: a review. Parasit Vectors. 2018 Apr 24;11(1):264–264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5937836</ArticleId>
            <ArticleId IdType="pubmed">29690895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lima MES, Bachur TPR, Aragão GF. Guillain-Barre syndrome and its correlation with dengue, Zika and
chikungunya viruses infection based on a literature review of reported cases
in Brazil. Acta Trop. 2019;197:105064–105064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31220435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D. An update on Zika virus infection. Lancet. 2017 Nov 04;390(10107):2099–2109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28647173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharp TM, Fischer M, Muñoz-Jordán JL, Paz-Bailey G, Staples JE, Gregory CJ, et al.  Dengue and Zika virus diagnostic testing for patients with a
clinically compatible illness and risk for infection with both
viruses. MMWR Recommendations Report. 2019;68(1):1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6581290</ArticleId>
            <ArticleId IdType="pubmed">31194720</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
